Molecular Partners AG Reports Positive Phase 1/2a Trial Results for MP0533 in AML

Molecular Partners AG has announced updated data from its ongoing Phase 1/2a clinical trial of MP0533, a multispecific T-cell engager, in patients with acute myeloid leukemia (AML). The company presented these results in a poster session at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place from December 6-9, 2025, in Orlando, Florida. The trial data indicated that accelerated step-up dosing and higher dosing frequency of MP0533 are feasible and result in increased drug exposure. Clinical benefit was observed with an acceptable safety profile across nine tested dosing regimens. Six of eight responders had low bone marrow blast counts at baseline, suggesting further evaluation of MP0533 in this patient subgroup may be warranted. Molecular Partners is considering additional studies of MP0533 in both relapsed/refractory and front-line AML settings, potentially in combination with standard care. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007798), on December 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here